论文部分内容阅读
目的:研究静脉给予大鼠人参皂苷Rg2后,其在胆汁、粪便和尿液中的排泄。方法:采用反相高效液相色谱(HPLC)-紫外检测器(UVD)法测定大鼠胆汁、粪便和尿液中的人参皂苷Rg2;Dikma Diamonsil TMC18色谱柱(4.6 mm×250 mm,5μm),以甲醇-4%磷酸水溶液(65∶35)为流动相,检测波长为203 nm。结果:HPLC-UVD测定方法的标准曲线线性关系、样品回收率和日内、日间精密度均符合生物样品分析要求。给大鼠静脉注射人参皂苷Rg2后,5.5 h内胆汁中原形人参皂苷Rg2累积排泄量为给予剂量的27.2%,24 h内粪便中原形人参皂苷Rg2累积排泄量为给予剂量的22.6%;尿液中未检出人参皂苷Rg2。结论:静脉给予大鼠人参皂苷Rg2,原形药物主要通过胆汁和粪便途径排出体外。
Objective: To study the excretion of rat ginsenoside Rg2 in bile, feces and urine after intravenous administration. METHODS: Ginsenoside Rg2 in rat bile, feces and urine was determined by reverse phase high performance liquid chromatography (HPLC) - ultraviolet detector (UVD). Dikma Diamonsil TMC18 column (4.6 mm × 250 mm, 5 μm) Methanol-4% phosphoric acid solution (65:35) as the mobile phase, detection wavelength of 203 nm. Results: The calibration curve of HPLC-UVD was linear, the recovery of samples and the intra-day and inter-day precision all met the requirements of biological sample analysis. After intravenous administration of ginsenoside Rg2 to rats, the cumulative excretion of ginsenoside Rg2 in bile in 5.5 h was 27.2% of the given dose, and the cumulative excretion of ginsenoside Rg2 in excrement in 24 h was 22.6% of the given dose. Urine Ginsenoside Rg2 was not detected. Conclusion: The rat ginsenoside Rg2 is intravenously administered. The prototype drugs are mainly excreted through bile and feces.